Sanofi partners with OpenAI, Formation Bio on AI-driven drug development


FILE PHOTO: The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes

(Reuters) - French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Intelligence.

Sanofi said in a statement that the partnership with OpenAi will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources.

Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.

(Reporting by Augustin Turpin, editing by Tassilo Hummel)

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

   

Next In Tech News

YouTube and Instagram outpace Netflix in some countries
From data to drugs: How AI is revolutionising drug development
YouTube: We will cancel Premium subscriptions bought via foreign VPN
'Listen to this page': Chrome can now read websites aloud on Android
Human voice or deepfake? Our brains can tell the difference – for now
European vacation too expensive? Try a virtual vacation with these video games
This humanoid robot can drive a car
‘Pebbling’ is a love language for the digital age
How quantum physics could help lasers perform better in fog and aid communications
This technology could recharge drones wirelessly over long distances

Others Also Read